GlaxoSmithKline, Europe's largest drugmaker, has increased its stake in Addex Pharmaceuticals to five percent, the biotechnology firm said on Wednesday, November 12.
S.R. One Ltd, the venture capital arm of GlaxoSmithKline’s independent corporate healthcare venture capital fund, now has a total of 293,125 Addex shares, corresponding to five percent of the voting rights, Addex said.
Shares in Geneva-based Addex, which listed on the Zurich exchange last year, hit a year high of CHF50.85 in September but have since fallen to CHF34.
Bookmark with:
- Digg
- Reddit
- Del.icio.us
- Facebook
- Newsvine
Sign Up to Exec UK now for FREE!